🇺🇸 FDA
Patent

US 10730948

Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10730948 (Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/577